** Shares of Clarity Pharmaceuticals CU6.AX jumps 12.4% to A$1.885, highest since April 3
** The radiopharmaceutical company gets R&D tax incentive refund to develop its Targeted Copper Theranostic (TCT) platform to diagnose and treat various cancers
** Co also signs deal for supply of copper-64 isotope, which is used along with copper-67 in TCT platforms
** Despite the day's gains, the stock is down about 55% YTD
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((JasmeenAraIslam.Shaikh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。